BioPharmSignal logoBioPharmSignal

Biotech News

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

Outlook (OTLK)OutlookFinancing

ISELIN, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of its previously announced public offering of

Open original release

Related news

OTLKOutlook2026-05-28 20:00 EST

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

OTLKOutlook2026-03-25 20:05 EST

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

MGTXMeiraGTx2026-04-16 11:48 EST

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

HROWHarrow, Inc.2026-03-24 20:57 EST

Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

PRQRProQR Therapeutics2026-06-25 10:35 EST

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

OCGNOcugen2026-05-04 20:01 EST

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

HROWHarrow, Inc.2026-03-24 12:15 EST

Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

KPRXKiora Pharmaceuticals2026-04-07 11:00 EST

Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

LENZLenz Therapeutics Inc2026-07-06 12:15 EST

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

OCGNOcugen2026-05-05 12:12 EST

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

View all latest news

Outlook

Outlook Therapeutics is an ophthalmology company focused on retinal disease and anti-VEGF therapy delivery. Its story centers on whether it can create a differentiated eye-care franchise.

Recent company news

OTLKOutlook2026-06-01 12:46 EST

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

OTLKOutlook2026-05-28 20:00 EST

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

OTLKOutlook2026-05-26 11:00 EST

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

OTLKOutlook2026-05-15 20:05 EST

Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

OTLKOutlook2026-04-23 20:05 EST

Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

Stock data

Close
0.90 USD
Market cap
120.89M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States